High-Dose Vitamin D for Multiple Sclerosis: The Co…

The Coimbra Protocol is a high-dose vitamin D approach for autoimmune diseases, particularly multiple sclerosis, developed by Brazilian neurologist Dr. Cicero Gama Coimbra. It involves doses of vitamin D that are orders of magnitude above standard supplementation — typically 40,000 to 100,000 IU per day — combined with specific dietary restrictions and mandatory co-factor supplementation. While the protocol has generated a devoted following among MS patients who report significant symptom reduction and relapse prevention, it is not without controversy and requires strict medical supervision.

The Protocol Overview

The core premise of the Coimbra Protocol is that many autoimmune patients have a genetic resistance to vitamin D signaling, requiring supraphysiological doses to achieve the immunomodulatory effects that normal doses would produce in vitamin D-sensitive individuals. Dr. Coimbra and his colleagues report treating thousands of MS patients with this approach, with case series and observational data suggesting high rates of relapse reduction and disability stabilization.

Doses in the protocol are individualized but typically range from 40,000 to 100,000 IU vitamin D3 daily, targeting serum 25-OH vitamin D levels of 200 to 400 ng/mL — far above the 50 to 80 ng/mL range considered optimal in standard medicine. At these doses, hypercalcemia (elevated blood calcium) is the primary toxicity risk, which is managed through several mandatory protocol components.

Mandatory Co-Factors

Vitamin K2 is perhaps the most critical co-factor at high vitamin D doses. Vitamin D increases calcium absorption significantly, and without adequate K2 to activate matrix Gla protein (MGP) and osteocalcin, calcium can deposit in soft tissues including blood vessels and kidneys. The Coimbra Protocol requires 200 to 1,000 mcg MK-7 daily depending on dose.

Magnesium is essential for vitamin D metabolism — it is a cofactor for enzymes that convert vitamin D to its active form. Vitamin D supplementation without magnesium can actually deplete magnesium stores. The protocol requires 400 to 1,000 mg magnesium daily (in forms like magnesium glycinate or taurate that don't cause excessive GI effects).

Omega-3 fatty acids are included for their anti-inflammatory synergy and support of the protocol's immune-modulating goals.

The Low-Calcium Diet Requirement

The most demanding aspect of the Coimbra Protocol is the strict low-calcium diet required to prevent hypercalcemia at megadose vitamin D levels. Patients must eliminate dairy products and other high-calcium foods and maintain calcium intake below 500 mg per day. This is combined with drinking 2.5 liters of water daily to promote urinary calcium excretion.

Without this dietary restriction, megadose vitamin D will cause dangerous hypercalcemia with symptoms including fatigue, confusion, excessive thirst, kidney stones, and potentially kidney failure. The dietary requirement is non-negotiable at these doses.

Evidence Base

Formal randomized controlled trials of the full Coimbra Protocol are limited. The evidence base consists primarily of Dr. Coimbra's case series, observational cohort data from practitioners trained in the protocol, and several smaller controlled studies using high-dose vitamin D (though not always at Coimbra protocol levels).

A notable published observational study from Brazil followed 106 MS patients over 12 months using high-dose vitamin D (average 41,833 IU/day) and found a significant reduction in relapse rate. Other observational data shows that many patients achieve stable disease or clinical improvement, though selection bias in these reports limits conclusions.

The strongest mechanistic support comes from the well-established immunomodulatory effects of vitamin D at physiological doses, extrapolated to suggest that supraphysiological levels would produce proportionally greater immune regulation. Critics note this extrapolation may not hold linearly and that safety at very high doses requires more long-term data.

Medical Supervision Requirements

The Coimbra Protocol is explicitly designed to be practiced only under the supervision of a physician trained in the protocol. Blood tests including calcium, phosphate, 25-OH vitamin D, PTH, and urinary calcium excretion are monitored at regular intervals (typically every 3 to 6 months). Any signs of hypercalcemia — even subtle ones — require dose adjustment.

Patients interested in this approach should seek a physician listed in the official Coimbra Protocol practitioner directory. Attempting megadose vitamin D supplementation without the dietary restrictions, co-factors, and monitoring is dangerous and not what the protocol involves.

Who Is a Candidate

The protocol is primarily studied and used in MS, but Dr. Coimbra has applied it to other autoimmune conditions including psoriasis, lupus, and vitiligo. Within MS, it appears to be used most commonly in relapsing-remitting MS where relapse prevention is the primary goal. Patients considering the protocol should discuss it with both their neurologist and a Coimbra-trained practitioner.

Kidney disease, hyperparathyroidism, granulomatous diseases (sarcoidosis, tuberculosis), and certain medications are contraindications. Thiazide diuretics in particular increase hypercalcemia risk at high vitamin D doses.

FAQ

Q: Can I try the Coimbra Protocol without a doctor?

No. At doses of 40,000 to 100,000 IU daily, hypercalcemia is a genuine and potentially serious risk without the dietary restrictions, co-factors, and monitoring the protocol requires. Self-administering megadose vitamin D without medical supervision is dangerous.

Q: How does the protocol differ from standard vitamin D supplementation?

Standard supplementation targets 50 to 80 ng/mL serum levels with 2,000 to 5,000 IU daily. The Coimbra Protocol targets 200 to 400 ng/mL with 40,000 to 100,000 IU daily — a fundamentally different therapeutic approach requiring different management.

Q: Does the protocol interfere with MS disease-modifying drugs?

Some patients on the Coimbra Protocol discontinue DMTs in consultation with their neurologist. Others continue both. This decision should be made by the neurologist based on individual disease activity and response.

Q: Are there long-term safety data for the protocol?

Dr. Coimbra has treated patients for over a decade, and the observational record suggests good safety when dietary and monitoring requirements are followed. Formal long-term safety trials are lacking. This is a legitimate limitation of the evidence base.

Track your supplements in Optimize.

High-Dose Vitamin D for Multiple Sclerosis: The Coimbra Protocol